BRPI0606870A2 - composto de indol e uso do mesmo - Google Patents
composto de indol e uso do mesmoInfo
- Publication number
- BRPI0606870A2 BRPI0606870A2 BRPI0606870-7A BRPI0606870A BRPI0606870A2 BR PI0606870 A2 BRPI0606870 A2 BR PI0606870A2 BR PI0606870 A BRPI0606870 A BR PI0606870A BR PI0606870 A2 BRPI0606870 A2 BR PI0606870A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- sinusitis
- chronic
- useful
- leukotriene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
COMPOSTO DE INDOL E USO DO MESMO. A presente invenção se refere a um composto representado pela fórmula (I) onde todos os simbolos são conforme definido no relatório descritivo, um sal do mesmo, um solvato do mesmo ou uma pró-droga do mesmo, cujo composto apresenta atividade antagonística do receptor de leucotrieno, a qual se espera de ser mais efetiva que aquela dos antagonistas de receptores de leucotrieno atualmente usados em experimentos clínicos. Portanto, o composto da presente invenção é também de utilidade na prevenção e/ou tratamento de doenças mediadas pelo receptor de leucotrieno, tais como, as doenças respiratórias (como, por exemplo, asma brónquica, doença pulmonar obstrutiva crónica, enfisema pulmonar, bronquite crónica, pneumonia (incluindo pneumonite intersticial)), síndrome respiratória aguda grave (SARS), síndrome aguda de aflição respiratória (ARDS), rinite alérgica, sinusite (incluindo sinusite aguda, sinusite crónica, etc.), e de utilidade como um expectorante ou um agente antítussigeno.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005051392 | 2005-02-25 | ||
JP2005352787 | 2005-12-07 | ||
PCT/JP2006/303374 WO2006090817A1 (ja) | 2005-02-25 | 2006-02-24 | インドール化合物およびその用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0606870A2 true BRPI0606870A2 (pt) | 2009-07-21 |
Family
ID=36927451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0606870-7A BRPI0606870A2 (pt) | 2005-02-25 | 2006-02-24 | composto de indol e uso do mesmo |
Country Status (15)
Country | Link |
---|---|
US (1) | US7728023B2 (pt) |
EP (1) | EP1852420B1 (pt) |
JP (1) | JP5024039B2 (pt) |
KR (1) | KR101377790B1 (pt) |
CN (1) | CN101128424A (pt) |
AU (1) | AU2006216170B2 (pt) |
BR (1) | BRPI0606870A2 (pt) |
CA (1) | CA2599348C (pt) |
ES (1) | ES2395929T3 (pt) |
IL (1) | IL185199A (pt) |
MX (1) | MX2007010112A (pt) |
NO (1) | NO20074670L (pt) |
NZ (1) | NZ560513A (pt) |
RU (1) | RU2416601C2 (pt) |
WO (1) | WO2006090817A1 (pt) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2007756T3 (pl) | 2006-04-07 | 2016-01-29 | Vertex Pharma | Modulatory transporterów posiadających kasetę wiążącą ATP |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
PL2051962T3 (pl) | 2006-08-07 | 2012-03-30 | Actelion Pharmaceuticals Ltd | Pochodne kwasu (3-amino-1,2,3,4-tetrahydro-9h-karbazol-9-ilo)-octowego |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
US8445679B2 (en) | 2007-04-16 | 2013-05-21 | Abbvie Inc. | 7-substituted indole MCL-1 inhibitors |
JP5313229B2 (ja) | 2007-04-19 | 2013-10-09 | グラクソ グループ リミテッド | スフィンゴシン1−リン酸(s1p)アゴニストとして用いるためのオキサジアゾール置換インダゾール誘導体 |
JP5086027B2 (ja) * | 2007-10-15 | 2012-11-28 | 株式会社Adeka | インドリウム化合物及び該化合物を用いた光学記録材料 |
GB0807910D0 (en) * | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
JP2011524880A (ja) * | 2008-06-20 | 2011-09-08 | グラクソ グループ リミテッド | 化合物 |
TWI469965B (zh) * | 2008-12-22 | 2015-01-21 | Ono Pharmaceutical Co | 乙炔基吲哚化合物 |
US8809382B2 (en) | 2009-05-04 | 2014-08-19 | The Royal Institution For The Advancement Of Learning/Mcgill University | 5-oxo-ETE receptor antagonist compounds |
US9790186B2 (en) | 2009-07-21 | 2017-10-17 | Trustees Of Dartmouth College | Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection |
US8697869B2 (en) | 2010-03-22 | 2014-04-15 | Actelion Pharmaceuticals Ltd. | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivatives and their use as prostaglandin D2 receptor modulators |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
SG184987A1 (en) | 2010-04-22 | 2012-11-29 | Vertex Pharma | Process of producing cycloalkylcarboxamido-indole compounds |
WO2011162222A1 (ja) * | 2010-06-21 | 2011-12-29 | 小野薬品工業株式会社 | 4,4'-[4-フルオロ-7-({4-[4-(3-フルオロ-2-メチルフェニル)ブトキシ]フェニル}エチニル)-2-メチル-1h-インドール-1,3-ジイル]ジブタン酸、4,4'-[2-メチル-7-({4-[4-(ペンタフルオロフェニル)ブトキシ]フェニル}エチニル)-1h-インドール-1,3-ジイル]ジブタン酸および4,4'-[4-フルオロ-2-メチル-7-({4-[4-(2,3,4,6-テトラフルオロフェニル)ブトキシ]フェニル}エチニル)-1h-インドール-1,3-ジイル]ジブタン酸の新規結晶形 |
LT2697223T (lt) | 2011-04-14 | 2016-10-10 | Actelion Pharmaceuticals Ltd. | 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido[1,2-a]indolacto rūgšties dariniai ir jų, kaip prostaglandino d2 receptoriaus moduliatorių, panaudojimas |
CN103159665B (zh) * | 2011-12-09 | 2017-01-25 | 天津市国际生物医药联合研究院 | 对sars冠状病毒主蛋白酶具有抑制作用的靛红‑5‑酰胺类抑制剂 |
AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
WO2014141110A2 (en) * | 2013-03-14 | 2014-09-18 | Curadev Pharma Pvt. Ltd. | Aminonitriles as kynurenine pathway inhibitors |
JP6244036B2 (ja) * | 2014-01-21 | 2017-12-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 呼吸器合胞体ウイルス感染症の処置および予防のためのイミダゾール |
PL3119779T3 (pl) | 2014-03-17 | 2019-01-31 | Idorsia Pharmaceuticals Ltd | Pochodne kwasu azaindolooctowego i ich zastosowanie jako modulatorów receptora prostaglandyny d2 |
AU2015233046A1 (en) | 2014-03-18 | 2016-11-03 | Idorsia Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators |
US10206877B2 (en) | 2014-04-15 | 2019-02-19 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
CA2980221C (en) * | 2015-03-31 | 2024-03-12 | The Royal Institution For The Advancement Of Learning/Mcgill University | Indole analogs as 5-oxo-ete receptor antagonists and method of use thereof |
WO2017035288A1 (en) * | 2015-08-27 | 2017-03-02 | Trustees Of Dartmouth College | Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection |
AU2016323262B2 (en) | 2015-09-15 | 2020-11-19 | Idorsia Pharmaceuticals Ltd | Crystalline forms |
AU2017320582B2 (en) * | 2016-09-02 | 2023-11-16 | Arrowhead Pharmaceuticals, Inc | Targeting ligands |
CN112891343B (zh) * | 2021-03-22 | 2022-04-01 | 华中农业大学 | 3-吲哚乙腈在制备抑制新型冠状病毒SARS-CoV-2药物中的应用 |
KR20230140401A (ko) * | 2022-03-25 | 2023-10-06 | 주식회사 미토이뮨테라퓨틱스 | 항바이러스용 약학적 조성물 및 이의 용도 |
CN114874124B (zh) * | 2022-05-12 | 2023-07-04 | 五邑大学 | 一种褪黑激素肉桂酸衍生物及其制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607294D0 (en) * | 1985-04-17 | 1986-04-30 | Ici America Inc | Heterocyclic amide derivatives |
PT93943A (pt) * | 1989-05-05 | 1991-02-08 | Searle & Co | Processo para a preparacao de composicoes contendo compostos indole-2-carboxilato para tratamento de perturbacoes do snc |
US5229413A (en) | 1989-05-05 | 1993-07-20 | G. D. Searle & Co. | Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders |
US5530019A (en) | 1993-04-05 | 1996-06-25 | Fujisawa Pharmaceutical Co., Ltd. | Indole derivatives useful as testosterone 5α-reductase inhibitors |
US5968745A (en) | 1995-06-27 | 1999-10-19 | The University Of North Carolina At Chapel Hill | Polymer-electrodes for detecting nucleic acid hybridization and method of use thereof |
ATE186528T1 (de) * | 1995-10-10 | 1999-11-15 | Pfizer | Indol-carbamate als leukotriene antagonisten |
GB9902455D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
AU2001270200A1 (en) | 2000-06-27 | 2002-01-08 | Smith Kline Beecham Corporation | Fatty acid synthase inhibitors |
US6867224B2 (en) | 2002-03-07 | 2005-03-15 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods of preparation |
AU2003214462A1 (en) | 2002-04-03 | 2003-10-13 | Astrazeneca Ab | Indole derivatives having anti-angiogenetic activity |
ATE361910T1 (de) * | 2002-04-23 | 2007-06-15 | Aventis Pharma Inc | 3-(pyridinyl-amino)-1h-indol-2-carbonsäure- verbindungen als inhibitoren der interleukin-4 genexpression |
SE0202241D0 (sv) * | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
JP2006525366A (ja) | 2003-04-30 | 2006-11-09 | ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー | 複素環式カルボン酸置換基 |
EP2481732A1 (en) * | 2003-09-01 | 2012-08-01 | Ono Pharmaceutical Co., Ltd. | Condensed ring compound and use thereof |
-
2006
- 2006-02-24 NZ NZ560513A patent/NZ560513A/en not_active IP Right Cessation
- 2006-02-24 JP JP2007504797A patent/JP5024039B2/ja not_active Expired - Fee Related
- 2006-02-24 RU RU2007135347/04A patent/RU2416601C2/ru not_active IP Right Cessation
- 2006-02-24 WO PCT/JP2006/303374 patent/WO2006090817A1/ja active Application Filing
- 2006-02-24 EP EP06714513A patent/EP1852420B1/en not_active Not-in-force
- 2006-02-24 CN CNA2006800057910A patent/CN101128424A/zh active Pending
- 2006-02-24 ES ES06714513T patent/ES2395929T3/es active Active
- 2006-02-24 CA CA2599348A patent/CA2599348C/en not_active Expired - Fee Related
- 2006-02-24 MX MX2007010112A patent/MX2007010112A/es active IP Right Grant
- 2006-02-24 BR BRPI0606870-7A patent/BRPI0606870A2/pt not_active IP Right Cessation
- 2006-02-24 US US11/885,018 patent/US7728023B2/en not_active Expired - Fee Related
- 2006-02-24 AU AU2006216170A patent/AU2006216170B2/en not_active Ceased
- 2006-02-24 KR KR1020077019358A patent/KR101377790B1/ko not_active IP Right Cessation
-
2007
- 2007-08-12 IL IL185199A patent/IL185199A/en not_active IP Right Cessation
- 2007-09-13 NO NO20074670A patent/NO20074670L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP5024039B2 (ja) | 2012-09-12 |
RU2416601C2 (ru) | 2011-04-20 |
KR20070114140A (ko) | 2007-11-29 |
US7728023B2 (en) | 2010-06-01 |
AU2006216170B2 (en) | 2012-02-09 |
AU2006216170A1 (en) | 2006-08-31 |
NO20074670L (no) | 2007-11-19 |
JPWO2006090817A1 (ja) | 2008-07-24 |
CA2599348C (en) | 2013-07-23 |
CN101128424A (zh) | 2008-02-20 |
EP1852420A1 (en) | 2007-11-07 |
NZ560513A (en) | 2010-07-30 |
MX2007010112A (es) | 2007-10-12 |
US20080188532A1 (en) | 2008-08-07 |
EP1852420A4 (en) | 2011-06-15 |
CA2599348A1 (en) | 2006-08-31 |
IL185199A (en) | 2014-06-30 |
IL185199A0 (en) | 2008-01-06 |
EP1852420B1 (en) | 2012-10-17 |
KR101377790B1 (ko) | 2014-03-27 |
RU2007135347A (ru) | 2009-03-27 |
ES2395929T3 (es) | 2013-02-18 |
WO2006090817A1 (ja) | 2006-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0606870A2 (pt) | composto de indol e uso do mesmo | |
CR9832A (es) | Compuestos de pirimidina amida como inhibidores de pgds | |
NO20091183L (no) | Derivater av 4-(N-azacykloalkyl)-anilider, fremgangsmåte for fremstilling av slike forbindelser, preparater omfattende slike forbindelser samt anvendelse av slike forbindelser for forhindring eller behandling av sykdom | |
NO20090723L (no) | Kondenserte heterosykliske derivater og fremgangsmater for anvendelse | |
BRPI0606324A2 (pt) | derivados de purina agindo como agonistas de receptor de a2a | |
NO20083501L (no) | Azaindoler som er anvendelige som inhibitorer for Janus-kinaser | |
NO20064976L (no) | Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser | |
NO20091326L (no) | Indazolderivater som modulatorer av interleukin-1-reseptor-assosiert kinase | |
BRPI0511424A (pt) | composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para a preparação de um composto | |
BRPI0911243B8 (pt) | derivados de benzofurano, benzotiofeno, benzotiazol, e composição farmacêutica | |
WO2008027584A3 (en) | 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase | |
BR0107934A (pt) | Carboxamidas de pirimidina úteis como inibidores de isozimas pde4 | |
NO20085099L (no) | Puritonderivativer som HM74A agonister | |
BRPI0413330A (pt) | inibidores de fosfodiesterase do tipo iv, composição farmacêutica contendo os mesmos e processo para sua preparação | |
NO20082090L (no) | Pyridopyrimidinoninhibitorer av P13K alfa | |
NO20083918L (no) | Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser | |
NO20084747L (no) | Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser | |
NO20076093L (no) | Substituerte amidderivater som proteinkinaseinhibitorer | |
WO2007041130A3 (en) | Deazapurines useful as inhibitors of janus kinases | |
NO20052595L (no) | Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser. | |
NO20076450L (no) | Heterosykliske forbindelser som nikotinsyrereseptoragonister for behandling av dyslipidemi | |
NO20083567L (no) | Hydantoinderivater for behandling av inflammatoriske forstyrrelser | |
MY154895A (en) | Pyrimidine hydrazide compounds as pgds inhibitors | |
CL2008001593A1 (es) | Compuestos derivados de heterociclos, antagonistas para el ccr2; y uso de los compuestos para tratar afecciones o enfermedades del tracto respiratorio, como enfermedad pulmonar obstructiva cronica y asma. | |
NO20082124L (no) | Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2450 DE 19-12-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |